secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2022-04-20T23:59:59+00:00
Accession:  0001104659-22-047560
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q1 sales $11.9B (+13.8%), adjusted EPS $1.73; full-year guidance reaffirmed
--------------------------------------------------------------------------------

- Q1 sales $11.9B, +13.8% reported, +17.5% organic; GAAP EPS $1.37, adjusted EPS $1.73.
- Global COVID-19 testing sales $3.3B in Q1; full-year testing sales projected ~$4.5B, mostly in H1.
- Full-year 2022 adjusted EPS guidance reaffirmed at least $4.70; GAAP EPS at least $3.35.
- Nutrition sales -7% reported (-4.4% organic) due to infant formula recall; excluding recall, Nutrition +5%.
- Medical Devices +7.4% reported (+11.5% organic); FreeStyle Libre sales ~$1.0B (+20.4% reported).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000110465922047560/0001104659-22-047560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000110465922047560/tm2213006d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-047560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer